Switching as only temporal solution for patients with antipsychotic-associated diabetes: further observations

Psychiatr Danub. 2007 Jun;19(1-2):87-8.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects*
  • Blood Glucose / metabolism
  • Body Mass Index
  • Clozapine / administration & dosage
  • Clozapine / adverse effects
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / chemically induced*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Dibenzothiazepines / administration & dosage
  • Dibenzothiazepines / adverse effects
  • Diet, Diabetic
  • Drug Therapy, Combination
  • Female
  • Fluphenazine / administration & dosage
  • Fluphenazine / analogs & derivatives
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Mass Screening
  • Quetiapine Fumarate
  • Risk Factors
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents
  • Blood Glucose
  • Dibenzothiazepines
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Quetiapine Fumarate
  • fluphenazine depot
  • Clozapine
  • Fluphenazine